Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2021-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to evaluate the efficacy and safety of a combination of the anti-CD20 monoclonal antibody Rituximab, Dexamethasone, daily high dose Cytarabine twice, and Carboplatin; delivered in an outpatient setting.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: La Raza Medical Center
• Treatments: BB 1101; Carboplatin; Cytarabine; Dexamethasone; Dexamethasone acetate; Lenograstim; Rituximab

Criteria

Inclusion Criteria:

• Diagnosis of recurrent or refractory B-cell non-Hodgkin lymphoma

• Performance status: Eastern Cooperative Oncology Group 0-2

• At least three weeks from last chemotherapy

• Toxicities by Common Terminology Criteria Version 4.0 ≤ 1

• Glomerular filtration rate >50 ml/min

• Women of childbearing potential must use effective methods of contraception

Exclusion Criteria:

• Post-transplant relapse of lymphoma

• Central nervous system involvement of lymphoma

• Serious infections

• Known allergies to one or more of the experimental drugs

• Diabetes with glucose >200 mg/dl

• Pregnant or lactating females

• Known HIV or B Hepatitis positivity

• Known allergies to filgrastim